Zacks Investment Research upgraded shares of Biohaven Pharmaceutical (NYSE:BHVN) from a hold rating to a buy rating in a research note released on Monday. Zacks Investment Research currently has $25.00 price target on the stock.

According to Zacks, “Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company’s pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. “

A number of other equities research analysts have also issued reports on BHVN. Needham & Company LLC reissued a buy rating and issued a $36.00 target price on shares of Biohaven Pharmaceutical in a research report on Wednesday, November 15th. BidaskClub lowered Biohaven Pharmaceutical from a sell rating to a strong sell rating in a research report on Tuesday, November 14th. William Blair reissued an outperform rating on shares of Biohaven Pharmaceutical in a research report on Tuesday, October 3rd. Morgan Stanley reissued an overweight rating and issued a $38.00 target price (down previously from $47.00) on shares of Biohaven Pharmaceutical in a research report on Tuesday, October 3rd. Finally, Piper Jaffray Companies reissued a buy rating and issued a $54.00 target price on shares of Biohaven Pharmaceutical in a research report on Tuesday, September 12th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Biohaven Pharmaceutical has an average rating of Buy and an average target price of $38.17.

Shares of Biohaven Pharmaceutical (NYSE:BHVN) opened at $20.44 on Monday. Biohaven Pharmaceutical has a 1 year low of $17.00 and a 1 year high of $39.51.

In other Biohaven Pharmaceutical news, insider John Tilton sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $29.25, for a total value of $877,500.00. Following the completion of the transaction, the insider now directly owns 30,000 shares in the company, valued at $877,500. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Kimberly Gentile sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $21.99, for a total value of $109,950.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 439,131 shares of company stock valued at $12,011,701.

Hedge funds have recently bought and sold shares of the business. Legal & General Group Plc bought a new position in shares of Biohaven Pharmaceutical during the 3rd quarter worth approximately $119,000. Nationwide Fund Advisors bought a new position in shares of Biohaven Pharmaceutical during the 3rd quarter worth approximately $214,000. American International Group Inc. bought a new position in shares of Biohaven Pharmaceutical during the 3rd quarter worth approximately $251,000. State of Wisconsin Investment Board bought a new position in shares of Biohaven Pharmaceutical during the 3rd quarter worth approximately $262,000. Finally, Susquehanna International Group LLP bought a new position in shares of Biohaven Pharmaceutical during the 3rd quarter worth approximately $302,000. Hedge funds and other institutional investors own 47.76% of the company’s stock.

WARNING: “Biohaven Pharmaceutical (BHVN) Lifted to Buy at Zacks Investment Research” was originally reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://theolympiareport.com/2017/12/07/biohaven-pharmaceutical-bhvn-lifted-to-buy-at-zacks-investment-research.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Get a free copy of the Zacks research report on Biohaven Pharmaceutical (BHVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.